The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System

Abstract

The results indicate that by replacing salmeterol/fluticasone or formoterol/budesonide with indacaterol, there are possible cost savings for the Colombian health care system. This was demonstrated by both cost-effectiveness and budget impact models.

Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy

“…Exacerbations risk, utility values, mortality and costs are then estimated by GOLD stage [ Oostenbrink et al. 2005 ; Rutten-Van Molken et al 2007 ; Price et al 2011 , 2013 ; Ariza et al 2012 ].…”

“…While some previously published models in COPD have estimated the risk of both severe and moderate exacerbations by both treatment and GOLD stage, [ Ariza et al 2012 ; Price et al 2013 ] others have estimated overall exacerbation risk by treatment only [ Oostenbrink et al 2005 ; Price et al 2011 ] or estimated the proportion of severe to nonsevere exacerbations by GOLD stage [ Hoogendoorn et al 2014 ]. These approaches come with limitations, in that the estimated probability of exacerbation is not affected by past experience of exacerbation.…”